Surgical expense coverage provides benefits for physicians' charges associated with surgical procedures. While one tends to think of a surgical procedure as involving cutting, insurance contracts typically define the term broadly to include such procedures as suturing, electrocauterization, removal of a stone or foreign body by endoscopic means, and the treatment of fractures or dislocations.

ORIMtec offers you Intraoperative neurophysiological monitoring (IONM) in the operating room. Intraoperative neurophysiological monitoring (IONM) is an exciting medical/technical service provided in the operating room that has proven valuable in complex spinal and cranial surgical procedures. Intraoperative neurophysiological monitoring (IONM) is a real-time assessment of neurological function involving the brain, spinal cord and related nerve structures. Complex, multimodality IONM facilitates the surgical process and reduces surgical risk by enabling a neurotechnologist (NT) to alert your if and when spinal cord or neural structure compromise appears imminent. IONM works by using a biomedical computer to record impulses generated by electrical stimulation of peripheral nerves and the dermatomes of nerve roots. Using the International EEG 10-20 electrode placement system, needle electrodes are precisely placed into the scalp, at specific locations associated with the spinal column and along the course of related peripheral nerves. Knowledge of changes reflected in these recordings or the existence of a response in the case of EMG activity may help the surgeon protect the spinal cord and related neural structures, thereby reducing the possibility of a neurological deficit. Commonly monitored surgeries are those that involve the cervical, thoracic, lumbar and sacral areas of the spine, craniotomies, peripheral nerves and carotid/vertebral surgeries.

ORIMtec raises the standard of care through surgical monitoring. IONM plays an important role in reducing the risk of injury to the nervous system during head, neck and back surgeries, thus optimizing your potential for a successful surgical outcome. During your surgery the ORIMtec neurotechnologists will use electrodes to provide a virtual nerve “roadmap” that is used to monitor stimulation and conduction activities. Thousands of patients have benefited from their surgical monitoring services and the unique ORIMtec approach to care.

ORIMtec raises the standard of care through surgical monitoring. IONM plays an important role in reducing the risk of injury to the nervous system during head, neck and back surgeries, thus optimizing your potential for a successful surgical outcome. During your surgery the ORIMtec neurotechnologists will use electrodes to provide a virtual nerve “roadmap” that is used to monitor stimulation and conduction activities. Thousands of patients have benefited from their surgical monitoring services and the unique ORIMtec approach to care.

As Chief Medical Officer, you will most likely find that the opinions of your surgeons vary regarding intraoperative neuromonitoring (IONM). Those surgeons who embrace IONM are educated in its application and have probably observed or worked with a well-trained neuromonitoring team practicing complex, multimodality monitoring. This type of surgical monitoring applies all of the many diagnostic tools available. Knowing when to implement the appropriate modality at the appropriate time separates marginal monitoring groups from the highest quality of neuromonitoring conducted by well-trained neurotechnologists (NTs).

A 31-year-old man who died of metastatic adenocarcinoma of the sigmoid colon had undergone bilateral ureterosigmoidostomy for exstrophy of the bladder 20 years earlier. The patient never underwent a colonoscopy. Neoplastic transformation at the ureterosigmoid anastomosis must be considered as a possible severe complication, and therefore, periodic follow-up of these patients is mandatory.

PURPOSE: The occurrence of neoplasia after ureterosigmoidostomy is well-documented in the literature. Because of its rarity, few general surgeons will gain significant exposure to this entity, and colorectal surgeons are likely to be involved with the care of these patients. The purpose of this article is to apprise colorectal surgeons about the management of neoplasia after ureterosigmoidostomy and to familiarize them with the unique anatomy of the reconstructed pelvis. METHODS: We performed a MEDLINE search to identify articles on ureterosigmoid tumors. The theories regarding the cause and pathology of these tumors were critically analyzed. A consensus was developed for screening patients with ureterosigmoidostomy and for treatment of neoplasia. RESULTS: The incidence of carcinoma after ureterosigmoidostomy ranges from 2 to 15 percent. Polyps are more common, and it seems that these tumors also follow the sequence of adenocarcinoma that is seen in the common variety of colorectal neoplasia. Neoplastic changes begin with the interaction of urine and feces and the healing colonic mucosa. Both production of nitrosamines by the action of bacteria on urine and DNA damage caused by reactive oxygen radicals produced by neutrophils at the healing anastomosis have been implicated in the pathogenesis of neoplasia. The latent period between formation of ureterosigmoidostomy and the appearance of carcinoma is between 20 and 26 years. Obstructive urinary symptoms that develop more than two years after ureterosigmoidostomy should be viewed with suspicion. The patient should be investigated with a CT scan and colonoscopy, and a barium enema may be required to delineate the anatomy further. If a benign tumor is encountered during colonoscopy, it may be removed by snare polypectomy. For a malignant tumor the segment of colon with ureteric implants should be excised, along with its lymphatic drainage. Bowel continuity is restored primarily, and the ureters are implanted in an ileal conduit. CONCLUSIONS: Patients with ureterosigmoidostomy should be followed closely for the rest of their lives. The aim of screening is to identify and treat neoplasia before malignancy develops. Furthermore, early detection of neoplasia by close screening will improve survival. Although urine cytology and occult blood are inexpensive tests, colonoscopy remains the criterion standard for follow-up of these patients. Annual colonoscopic surveillance should be started soon after the ureterosigmoidostomy but not later than five to six years after the procedure. Patients who are noncompliant with the vigorous follow-up schedule should be offered the option of resection of the colonic segment at risk with urinary diversion.